Ergotamine Pharmacokinetics in Man: An Editorial

Schran HF Schwarz HJ Talbot KC Loeffler LJ. Specific radioimmunoassay of ergot peptide alkaloids in plasma. Clin Chem 1979;25:1928–33.

Heazlewood RL Eadie MJ. Ergotamine content of commercial ergotamine formulations. Aust J Pharm Sci 1980;9:90–1.

Edlund PO. Determination of ergot alkaloids in plasma by high-performance liquid chromatography and fluorescence detection. J Chromatogr 1981;226:107–15.

Eckert H Kiechel JR Rosenthaler J Schmidt R Schreier E. Biopharmaceutical aspects. Analytical methods, pharmacokinetics, metabolism and bioavailability. In Berde B Schild HO. edsErgot alkaloids and related compounds.Berlin:Springer,1978:719–803.

Eadie MJ. The use of ergotamine in migraine.Med J Aust [Suppl] 1972:26–29.

Hooper WD Sutherland JM Eadie MJ Tyrer JH. Fluorimetric assay of ergotamine. Anal Chim Acta 1974;69:11–17.

Sutherland JM Hooper WD Eadie MJ Tyrer JH. Buccal absorption of ergotamine. J Neurol Neurosurg Psychiatry 1974;37:1116–20.

Schmidt R Fanchamps A. Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol 1974;7:213–16.

Meier J Schreier E. Human plasma levels of some anti-migraine drugs. Headache 1976;16:96–104.

Aellig WH Nuesch E. Comparative pharmacokinetic investigations with tritium-labelled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol 1977;15:106–12.

Orton E. Ergotamine tartrate levels using radio-immunoassay. In Greene R. edCurrent concepts in migraine research.New York:Raven Press,1978:79–84.

Ala-Hurula V Myllyla VV Arvela P Heikkila J Karki N Hokkanen E. Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. Eur J Clin Pharmacol 1979;15:51–5.

Ala-Hurula V Myllyla VV Arvela P Karki NT Hokkanen E. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol 1979;16:355–60.

Ala-Hurula V. Correlation between clinical response to and plasma concentrations of ergotamine. Acta Neurol Scand[suppl 78],1980;62:232.

Hovdal H Syversen GB Rosenthaler J. Ergotamine in plasma and CSF after i.m. and rectal administration to humans. Cephalalgia 1982;2:145–50.

Ekbom K Paalzow L Waldenlind E. Low biological availability of ergotamine tartrate after oral dosing in cluster headaches. Cephalalgia 1981;1:203–7.

Tfelt-Hansen P Paalzow L Ibraheem JJ. Bioavailability of sublingual ergotamine. Br J Clin Pharmacol 1982;13:239–40.

Waldenlind E Ekbom K Krabbe AÆ Paalzow G Paalzow L Tfelt-Hensen P. Ergotamine for cluster headache. A pharmacokinetic study. Acta Neurol Scand[suppl. 90]1982;65:83–4.

Ibraheem JJ Paalzow L Tfelt-Hansen P. Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. Eur J Clin Pharmacol 1982;23:235–40.

Tfelt-Hansen P Eickhoff JH Olesen J. Duration of the biological effect of ergotamine tartrate. Adv Neurol 1982;33:315–19.